Tazeen Ahmad
Stock Analyst at B of A Securities
(3.00)
# 1,511
Out of 4,761 analysts
190
Total ratings
42.66%
Success rate
0.07%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $184 → $179 | $120.69 | +48.31% | 3 | Feb 7, 2025 | |
| PRTA Prothena Corporation | Maintains: Neutral | $26 → $22 | $15.56 | +41.39% | 5 | Dec 19, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $79 → $46 | $4.64 | +891.38% | 3 | Dec 18, 2024 | |
| KALV KalVista Pharmaceuticals | Initiates: Buy | $22 | $10.03 | +119.34% | 1 | Dec 18, 2024 | |
| PEPG PepGen | Maintains: Neutral | $10 → $6 | $1.37 | +337.96% | 2 | Nov 18, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $61 → $47 | $27.52 | +70.78% | 6 | Nov 6, 2024 | |
| INCY Incyte | Upgrades: Buy | $68 → $90 | $72.11 | +24.81% | 5 | Oct 30, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $13 → $15 | $9.19 | +63.22% | 5 | Oct 17, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $307 → $314 | $250.59 | +25.30% | 2 | Oct 14, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Neutral | $48 → $52 | $56.07 | -7.26% | 7 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $6 | $7.31 | -17.92% | 14 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $191 | $152.43 | +25.30% | 8 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $150 | $120.01 | +24.99% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $3.85 | -48.05% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $29 | $20.73 | +39.89% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $76 | $47.37 | +60.44% | 4 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $644.48 | -5.82% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $25 → $32 | $50.69 | -36.87% | 15 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $166 → $213 | $106.28 | +100.41% | 21 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $42.59 | +78.45% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $22 | $19.95 | +10.28% | 13 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.77 | +577.97% | 1 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $1.25 | +1,020.00% | 2 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $2.81 | +255.87% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.42 | +322.54% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $7.00 | +114.29% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $0.5 | $1.38 | -63.77% | 1 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $16.49 | -33.29% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $9.21 | +8.58% | 11 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $1.63 | +22.70% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $0.87 | +588.94% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $11.20 | +33.93% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $74.49 | -19.45% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.28 | +1,150.00% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $17.77 | +519.02% | 1 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $11.06 | +288.79% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $161.65 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $4.40 | +6,725.94% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $0.83 | +983.03% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $25.16 | +90.78% | 6 | Oct 10, 2018 |
Neurocrine Biosciences
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $120.69
Upside: +48.31%
Prothena Corporation
Dec 19, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $15.56
Upside: +41.39%
4D Molecular Therapeutics
Dec 18, 2024
Maintains: Buy
Price Target: $79 → $46
Current: $4.64
Upside: +891.38%
KalVista Pharmaceuticals
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $10.03
Upside: +119.34%
PepGen
Nov 18, 2024
Maintains: Neutral
Price Target: $10 → $6
Current: $1.37
Upside: +337.96%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $61 → $47
Current: $27.52
Upside: +70.78%
Incyte
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $72.11
Upside: +24.81%
Amicus Therapeutics
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $9.19
Upside: +63.22%
Alnylam Pharmaceuticals
Oct 14, 2024
Maintains: Buy
Price Target: $307 → $314
Current: $250.59
Upside: +25.30%
Rhythm Pharmaceuticals
Oct 14, 2024
Maintains: Neutral
Price Target: $48 → $52
Current: $56.07
Upside: -7.26%
Oct 9, 2024
Maintains: Underperform
Price Target: $11 → $6
Current: $7.31
Upside: -17.92%
Sep 23, 2024
Maintains: Buy
Price Target: $175 → $191
Current: $152.43
Upside: +25.30%
Sep 16, 2024
Maintains: Buy
Price Target: $125 → $150
Current: $120.01
Upside: +24.99%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $3.85
Upside: -48.05%
Sep 4, 2024
Maintains: Buy
Price Target: $25 → $29
Current: $20.73
Upside: +39.89%
Jun 25, 2024
Maintains: Buy
Price Target: $76
Current: $47.37
Upside: +60.44%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $644.48
Upside: -5.82%
Jun 21, 2024
Maintains: Underperform
Price Target: $25 → $32
Current: $50.69
Upside: -36.87%
Jun 21, 2024
Maintains: Buy
Price Target: $166 → $213
Current: $106.28
Upside: +100.41%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $42.59
Upside: +78.45%
May 10, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $19.95
Upside: +10.28%
May 8, 2024
Initiates: Buy
Price Target: $12
Current: $1.77
Upside: +577.97%
Apr 9, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $1.25
Upside: +1,020.00%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $2.81
Upside: +255.87%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.42
Upside: +322.54%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $7.00
Upside: +114.29%
Dec 14, 2023
Downgrades: Underperform
Price Target: $7 → $0.5
Current: $1.38
Upside: -63.77%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $16.49
Upside: -33.29%
Jul 13, 2023
Upgrades: Buy
Price Target: $10
Current: $9.21
Upside: +8.58%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $1.63
Upside: +22.70%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $0.87
Upside: +588.94%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $11.20
Upside: +33.93%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $74.49
Upside: -19.45%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.28
Upside: +1,150.00%
Sep 9, 2021
Initiates: Buy
Price Target: $110
Current: $17.77
Upside: +519.02%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $11.06
Upside: +288.79%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $161.65
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $4.40
Upside: +6,725.94%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $0.83
Upside: +983.03%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $25.16
Upside: +90.78%